Nitazoxanide is a prescription antiprotozoal medicine available in U.S. tablet and oral suspension formulations, including the Alinia brand. It is used for certain diarrheal infections involving Giardia lamblia and Cryptosporidium parvum according to its product labeling. Its clinical overlap with metronidazole lies in Giardia treatment, not in vaginal bacterial vaginosis products or rosacea skin formulations. A person seeking nitazoxanide should start with a clinical diagnosis and the exact oral product prescribed.
The distinction between tablets and suspension is especially important in pediatric care. Alinia labeling identifies 500 mg tablets for patients 12 years and older and a 100 mg/5 mL oral suspension for eligible younger patients. A small tablet or a lower quoted price does not authorize substitution for the pediatric suspension. A licensed prescriber and pharmacist must confirm the product and instructions for the actual patient.
For comparisons with metronidazole see metronidazole versus nitazoxanide for Giardia. The separate Alinia brand guide covers branded product identity. This page addresses legitimate pharmacy access to nitazoxanide as an ingredient and does not promise current stock or make treatment decisions.
A U.S. pharmacy order for nitazoxanide should identify the oral dosage form and the patient’s age before a seller or price comparison. Alinia 500 mg tablets are labeled for patients aged 12 years and older, while the 100 mg/5 mL oral suspension has labeled use beginning at age one and can also be prescribed to older patients. These forms are not interchangeable by dividing adult tablets or estimating a volume independently. A valid clinician-issued prescription, appropriate strength, package and pharmacist review are necessary for dispensing.
The table is a product-identification aid, not a method for choosing an antiparasitic medicine without diagnosis. Giardia and Cryptosporidium diarrhea are the FDA-labeled contexts for Alinia, subject to label limitations; the products are not substitutes for vaginal metronidazole or rosacea therapies. For the suspension, verify its post-reconstitution concentration and handling instructions instead of assuming the listed powder bottle is ready to dispense as a measured liquid.
| Buying question | Product-level answer |
|---|---|
| Active ingredient | Nitazoxanide |
| U.S. branded products | Alinia tablets and oral suspension |
| Labeled diarrhea pathogens | Giardia lamblia and Cryptosporidium parvum, subject to label limitations |
| Tablet form | 500 mg; labeled for ages 12 years and older |
| Suspension form | 100 mg/5 mL after reconstitution; eligible children age 1+ |
| Pharmacy checks | Age, route, strength, package and mixing directions |
| Metronidazole substitution | Not the same active ingredient; clinician decision needed |
| Status and pricing | Confirm actual FDA product and pharmacy quote, not live claims |
Diarrhea, bloating and abdominal discomfort can occur with giardiasis but also with many other conditions. A clinician may use stool testing and exposure history to determine whether Giardia is present, whether treatment is required and which medicine is suitable. Nitazoxanide has its own FDA-labeled protozoal-diarrhea indications; metronidazole is a distinct drug whose role in giardiasis follows different U.S. labeling. The Giardia treatment overview explains that clinical distinction.
CDC clinical-care guidance recommends assessing persistent symptoms rather than assuming each episode of diarrhea is another infection that needs treatment. Inability to maintain fluids, symptoms of dehydration or clinical deterioration call for prompt professional evaluation. This is particularly important for young children and medically vulnerable patients, whose immediate hydration needs take precedence over comparing pharmacy prices.
Alinia tablets contain 500 mg nitazoxanide and are labeled for patients aged 12 years and older. Alinia for oral suspension is 100 mg/5 mL after reconstitution and has labeled use in appropriate patients aged one year and older; the liquid is not restricted to children. An 11-year-old must not receive the 500 mg tablet in place of the prescribed pediatric suspension, because one tablet exceeds the labeled pediatric amount for that age group. The prescriber must set the actual regimen; this pharmacy guide does not supply patient-specific dosing.
Alinia powder for oral suspension must be mixed correctly by pharmacy personnel, labeled at 100 mg/5 mL and supplied with appropriate measuring instructions. Its DailyMed labeling says to shake well before each use, keep the container tightly closed, store the reconstituted suspension at room temperature and discard unused medicine seven days after mixing. The pharmacist should confirm the mixing date and the product-specific directions before the medicine is taken home.
Alinia is a brand name, while nitazoxanide is the active ingredient. Approved generic products may exist for particular forms, but the question of pharmacy substitution must be answered at the exact product level. A pharmacist can use official approval and therapeutic-equivalence references for the particular strength and dosage form rather than guessing from a shopping listing.
A generic tablet and branded suspension are different dosage forms, even though both contain nitazoxanide. An approved equivalent for one presentation does not make another form a routine pharmacy substitution. Verify the intended concentration and package, and ask the pharmacist to resolve any mismatch with the written order. The Giardia medication comparison addresses the distinct active drugs; it is not a basis for replacing one prescription with the other.
A clinician may select nitazoxanide after appropriate evaluation. The pharmacy then checks the order and supplies the specified oral presentation. Online pharmacy convenience does not replace a medical visit or a valid prescription. Verify the seller’s state licensing, U.S. contact information, and whether a licensed pharmacist is available for counseling.
Claims to sell unrestricted parasite medication, unknown overseas packages or unapproved substitutes should be treated with caution. The FDA’s safer-online-pharmacy guidance applies to tablets and suspension alike. Check that the order specifies the correct age-appropriate oral product and that a licensed pharmacist can answer questions about its preparation.
The price of adult nitazoxanide tablets and pediatric suspension may be quite different because of packaging and concentration. Insurance formulary rules, prior authorization, pharmacy network terms and current cash-pay quotes can affect out-of-pocket cost. A meaningful comparison matches the patient’s actual prescription rather than converting a suspension course into a per-tablet estimate.
If coverage is denied, ask the pharmacist or plan what documentation is needed. The prescriber may evaluate alternatives, but a website cannot select the replacement or guarantee discount eligibility. Matching package concentration is crucial because different oral forms may be processed differently by the payer even when both are listed as nitazoxanide.
A person may have ongoing symptoms after Giardia has cleared, experience reinfection, or have another cause of illness. CDC clinical guidance recommends considering these possibilities and appropriate testing rather than assuming that every recurrence calls for a different antiparasitic. Taking leftover medicine or using another family member’s prescription is inappropriate.
When there is a supply problem, the pharmacist can contact the prescriber for an adjusted plan. Changing from nitazoxanide to metronidazole, or vice versa, involves a clinical decision and not a routine generic exchange. The clinician may also consider whether new exposure, incomplete prior treatment or post-infectious symptoms explain the continued illness before selecting another medicine. For a direct product comparison, see the Giardia medication contrast.
Bring the results of stool testing if available, a history of travel or relevant exposures, previous treatment and the duration of diarrhea. For a child, the prescriber needs age and other clinical details to choose a product and dose. Ask whether the intended drug is nitazoxanide or metronidazole, because a pharmacy cannot substitute one for the other as though they were competing generics.
Discuss hydration and when to seek urgent care for dehydration or worsening illness. Treatment success should be assessed clinically and, when appropriate, with further testing, not by taking repeated antiparasitic courses whenever abdominal symptoms return.
Check whether the written order is for a 500 mg tablet or 100 mg/5 mL oral suspension and confirm the labeled age range. If the suspension was reconstituted, verify that the mixing date is documented, the container will be shaken before each dose and unused medicine is discarded after the label’s seven-day window. Ask for a dosing device with clear metric markings rather than estimating volume with a household spoon.
A package described only as Giardia medicine is inadequate. Ask the pharmacist to identify the ingredient, approved formulation, manufacturer or labeler and authorized directions, and to explain any proposed generic substitution. If stock is unavailable, the prescriber should manage any therapeutic change.
Yes. U.S. Alinia tablets and suspension are prescription medicines.
Its label includes diarrhea due to Giardia lamblia and Cryptosporidium parvum in specified populations, with important limitations.
The Alinia tablets are labeled for patients 12 years and older; younger eligible patients use an appropriately prescribed oral suspension.
No. They are distinct drugs with different approved indications and product forms.
Yes. Mixing, measuring, storage and disposal of the reconstituted liquid are product-specific and should follow the label and pharmacist directions.
Its referenced U.S. label concerns specific protozoal diarrhea infections, not bacterial vaginosis.
No. The dosage forms and labeled age groups differ.
No. Persistent diarrhea may have several causes and warrants appropriate evaluation.
Not as a generic exchange; a clinician must select any different treatment.
No. Approval and specific pharmacy inventory are separate issues.